Prof. Aaron Ciechanover Joins PTM Biosciences´ Scientific Advisory Board
PTM Biosciences is proud to announce that 2004 Nobel Prize laureate in Chemistry and distinguished influencer Prof. Aaron Ciechanover is now part of the company Scientific Advisory Board.
Prof. Aaron Ciechanover MD. DSc., is a distinguished research Professor in the Faculty of Medicine at the Technion, Israel Institute of Technology.
Among the numerous prizes Prof. Ciechanover received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize in Chemistry, along with Drs. Hershko and Rose, for the discovery of ubiquitin-mediated protein degradation.
Prof. Ciechanover will provide PTM Biosciences an expert opinion on the ubiquitin-proteasome system (UPS) from its basic biology to its clinical applications.
July 1, 2018
PTM Biosciences´ facility at the Caesarea Industrial Park opening
PTM Biosciences began operating from its new facility at the Caesarea Industrial Park. The facility includes a fully equipped central lab, offices and meeting areas. An opening event was held on May 24 hosting colleague and friends.
About Caesarea Industrial Park:
Caesarea Industrial Park is one of the largest and most advanced in Israel. The park is a unique campus that provides an ideal strategic basis for success to approximately 180 leading Israeli companies engaged in high-tech, biotechnology, medical devices, water technologies, traditional industry and more. The park enjoys a central location, located near main transportation hubs to Tel Aviv and Haifa, and caters to a train station that serves park employees.
May 24, 2018
First Patient Enrolled in a Clinical Study
to assess responsiveness to Immunotherapy in Melanoma patients
PTM Biosciences launched a clinical study to assess responsiveness to Immunotherapy in Melanoma patients. The multi-site, two-arm study will enroll approximately 80 Melanoma patients, treated with Immunotherapy.
As part of the planned study, PTM Biosciences will analyze liquid biopsies of Melanoma patients, treated with anti PD-1 Nivolumab or Pembrolizumab. Post Translational Modifications profiling in Melanoma patients is an important step toward achieving clinical data in regards to the responsiveness to Immunotherapy. Study outcomes will facilitate the identification of activity based precision medicine biomarkers.
The study is led by Dr. Jonathan Cohen and additional clinicians from the Hadassah Medical Organization, and is conducted in collaboration with additional sites in Israel and the U.S.